DERIVING A CUT-OFF FOR THE ELECSYS® β-AMYLOID (1–42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER’S DISEASE (AD)